Turkey Pharmaceutical Market Report: Drugs, Biologics and Industry Trends 2026-2034

0
53

IMARC Group, a leading global market research and management consulting firm, has published its latest market intelligence report on the Turkey pharmaceutical market size grew from USD 22.3 Billion in 2025 to USD 23.5 Billion in 2026. Looking forward, IMARC Group expects the market to reach USD 32.6 Billion by 2034, exhibiting a growth rate (CAGR) of 4.19% during 2026-2034, driven by the expanding healthcare sector and easy access to healthcare services, rising demand from a growing geriatric population, advancements in medical technology, and strategic investments by local and international pharmaceutical companies across the country.

The market is experiencing steady growth momentum as Turkey combines universal health coverage, a large domestic patient base, and a well-established manufacturing ecosystem. The Social Security Institution (SGK) administers universal health insurance covering approximately 95% of the population, which keeps demand for prescription medicines consistently high across hospitals and pharmacies. Turkey is also home to over 100 licensed pharmaceutical and raw material production facilities, and it has been a full member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) since 2018. This alignment with international quality standards supports both domestic supply and exports. Simultaneously, government policy is steering the industry toward localization of previously imported products, biotechnology development, and greater export capacity.

How AI is Reshaping the Future of the Turkey Pharmaceutical Market?

  • AI-Powered Drug Discovery and Clinical Trial Optimization: Machine learning platforms are helping Turkish pharmaceutical developers and research partners screen candidate molecules, identify suitable patient cohorts, and shorten trial design cycles. This is particularly relevant as Turkey positions itself as a regional hub for clinical trials and invests in biosimilars and biologics, where analytical precision directly affects development timelines and cost.
  • Intelligent Supply Chain and Cold Chain Management: AI-driven demand forecasting and route optimization tools are enabling manufacturers, wholesalers, and logistics providers to manage temperature-sensitive products such as vaccines, monoclonal antibodies, and therapeutic proteins. With Turkey acting as a gateway between Europe, the Middle East, and North Africa, predictive inventory models help reduce stock-outs, wastage, and delivery delays across pharmacy and hospital channels.
  • Digital Compliance and Pharmacovigilance Automation: AI-based tools are supporting market authorization holders in adapting to evolving regulatory requirements, including serialization, electronic leaflets, and QR-code-based patient information. Automated adverse event detection and regulatory document processing reduce compliance workload while improving patient safety monitoring across prescription and over-the-counter portfolios.

Grab a sample PDF of this report: https://www.imarcgroup.com/turkey-pharmaceutical-market/requestsample

Turkey Pharmaceutical Market Trends and Drivers:

The Turkey pharmaceutical market is witnessing steady expansion, fueled by the convergence of demographic change, broader healthcare access, supportive industrial policy, and accelerating investment in advanced therapies. A rapidly aging population is a foundational demand driver. More than 8.4 million people in Turkey are aged 65 years or above, and the Turkish Statistical Institute projects this group will rise from roughly 10% of the population to over 16% in the coming decades. This shift is escalating demand for medicines targeting cardiovascular diseases, diabetes, arthritis, and other chronic conditions, and it is prompting manufacturers to broaden portfolios for geriatric and long-term care.

Expanding access to healthcare services is further reinforcing consumption. The Turkish pharmaceutical and healthcare product market, covering prescription drugs, health-oriented foods, traditional herbal remedies, vitamins, and supplements, now sells roughly 2.6 billion units annually across retail and hospital channels, according to the Pharmaceutical Manufacturers Association of Türkiye (IEIS). Turkey ranks among the top 20 pharmaceutical markets globally by value, with the sector size estimated at around USD 11 Billion by IEIS. Trade flows also reflect the industry’s scale, with pharmaceutical imports of approximately USD 5.43 Billion and exports of approximately USD 2.3 Billion, and the export base continues to grow as local producers target neighboring regions.

Government support for domestic manufacturing and biotechnology is reshaping the competitive environment. The Ministry of Industry and Technology has reported that 161 healthcare-industry investments received incentive certificates, mobilizing more than TRY 70 billion in investment. The national Development Plan identifies pharmaceuticals and medical devices as priority sectors for localization, with the objective of reducing import dependence and strengthening supply security. Tax breaks, grants, and investment incentives are encouraging both Turkish and multinational companies to localize production of high-value specialty drugs and biologics. A leading example is the technology transfer partnership between Abdi İbrahim and biosimilar developer mAbxience, which enables local manufacture of a monoclonal antibody for cancer treatment that was previously imported, with production covering the process from cell cultivation to the final product at AbdiBio, one of the country’s largest biotech facilities.

Pricing and reimbursement policy remains a decisive market influence. Turkey applies reference pricing against a basket of EU countries and converts these prices into Turkish lira using a fixed euro rate that is periodically adjusted. For the current pricing period, the base euro rate was raised by approximately 17% to TRY 25.33 from TRY 21.67 previously, while the price protection threshold was set at TRY 87.34. These adjustments are designed to ease cost pressure on manufacturers facing currency volatility and to support medicine availability. Meanwhile, SGK negotiates discounts and cost-containment agreements for higher-cost technologies, and alternative reimbursement models are increasingly used for high-priced therapies, shaping how quickly innovative treatments reach patients.

Turkey Pharmaceutical Industry Segmentation:

The report has segmented the market into the following categories:

Breakup By Type:

  • Pharmaceutical Drugs
    • Cardiovascular Drugs
    • Dermatology Drugs
    • Gastrointestinal Drugs
    • Genito-Urinary Drugs
    • Hematology Drugs
    • Anti-Infective Drugs
    • Metabolic Disorder Drugs
    • Musculoskeletal Disorder Drugs
    • Central Nervous System Drugs
    • Oncology Drugs
    • Ophthalmology Drugs
    • Respiratory Diseases Drugs
  • Biologics
    • Monoclonal Antibodies (MAbs)
    • Therapeutic Proteins
    • Vaccines

Pharmaceutical drugs account for the largest type segment, driven by the broad prevalence of chronic and lifestyle diseases, strong government support for locally produced generics, and the wide reimbursement coverage provided through SGK. Cardiovascular, metabolic, and central nervous system therapies remain core volume contributors, while biologics are gaining momentum as local biosimilar production and technology transfer agreements expand.

Breakup By Nature:

  • Organic
  • Conventional

Conventional products hold the larger share, supported by the established base of synthetic generic and branded medicines in hospital and retail pharmacy channels, while organic offerings benefit from interest in traditional herbal remedies authorized by national regulators.

Breakup By Region:

  • Marmara
  • Central Anatolia
  • Mediterranean
  • Aegean
  • Southeastern Anatolia
  • Blacksea
  • Eastern Anatolia

Marmara represents the leading regional market, anchored by Istanbul’s dense population, concentration of pharmaceutical manufacturing and headquarters, and advanced hospital and distribution infrastructure. Central Anatolia and the Aegean regions follow, supported by major urban healthcare centers and growing investment in healthcare capacity.

Competitive Landscape:

The report provides a comprehensive analysis of the competitive landscape in the Turkey pharmaceutical market with detailed profiles of all major companies, including:

  • Abdi İbrahim İlaç Sanayi ve Ticaret A.Ş.
  • Eczacıbaşı Holding A.Ş. (Gensenta Pharmaceutical Industry and Trade Inc.)
  • Deva Holding A.Ş.
  • Nobel İlaç Sanayii ve Ticaret A.Ş.
  • Novartis Türkiye
  • Pfizer Türkiye
  • GSK Türkiye
  • Sanofi Türkiye
  • Takeda Türkiye
  • Menarini Turkey
  • Bristol Myers Squibb Türkiye
  • Amgen Türkiye

Recent News and Developments in Turkey Pharmaceutical Market

  • August 2026: The Turkish Competition Authority published its Preliminary Report on the Pharmaceutical Sector Inquiry and opened it for public consultation. The report outlines enforcement priorities across patent misuse, reimbursement-linked entry barriers, and exclusive distribution agreements, signaling closer scrutiny of competition from product development through retail distribution to patients.
  • March 2026: Turkey introduced updated medicinal product pricing rules effective 12 March. The euro/TL adjustment rate was raised to 65% of the previous year’s average, a pricing incentive was introduced for the first equivalent or generic product to accelerate market entry, and value-based pricing was incorporated into legislation.
  • March 2026: The Turkish Medicines and Medical Devices Agency (TITCK) published substantial revisions to its guideline on package information and patient information leaflets for human medicinal products, covering both prescription and over-the-counter medicines. Risk pictograms and anti-tampering features become mandatory from July 2026, with electronic leaflets and QR codes mandatory for most products from January 2027.
  • January 2024: Turkish Cargo introduced three new pharmaceutical logistics products, TK Pharma Standard, TK Pharma Extra, and TK Pharma Advanced, offering flexible solutions for different categories of pharmaceutical and medical shipments and strengthening cold chain capabilities for the country’s growing trade in medicines.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Media and Sales Contact

IMARC Group
Email:
sales@imarcgroup.com
United States: +1-201-971-6302
India: +91-120-433-0800
United Kingdom: +44-753-714-6104

 

Sponsor
Arama
Sponsor
Kategoriler
Daha Fazla Oku
Güncel Haberler
How IBPS Clerk Mock Test Papers Help in Exam Preparation
The IBPS Clerk examination demands not just knowledge but also speed, accuracy, and strategic...
İle Self Studys 2026-06-08 07:17:01 0 435
Sektörel Haberler
E-KYC Market Size, Share, Trends, Key Drivers, Demand and Opportunity Analysis
" According to the latest report published by Data Bridge Market Research, the E-KYC...
İle Kajal Khomane 2026-06-15 11:07:20 0 307
Spor ve Fitness
India vs England U19 World Cup Final 2026: The Ultimate Guide
The stage is set for a historic showdown at the Harare Sports Club as the two unbeaten giants of...
İle Sunil Kumar 2026-02-05 14:37:57 0 953
Spor ve Fitness
How Reddy Anna Book Focuses on Easy Access and Reliable Usage
In today's environment, users increasingly expect digital sports platforms to provide easy...
İle Reddyannaxbook Reddyannaxbook 2026-10-30 06:59:15 0 78
Spor ve Fitness
CNC Machine Tools Market Share Analysis and 9.99% CAGR Outlook
The Cnc Machine Tools Market size was valued at US$ 71.41 billion in 2025 and is projected to...
İle Rakesh Jogi 2026-10-29 07:07:40 0 80